The Direct Answer
Clinical trials show that psilocybin-assisted therapy produces significant reductions in PTSD symptoms in veterans, including those who have failed multiple prior treatments. The VA has not adopted psilocybin because it remains Schedule I under federal law — not because the evidence is insufficient. Multiple VA-affiliated researchers are conducting trials, and the evidence base is growing rapidly. Veterans who cannot wait for federal approval are accessing psilocybin through state-legal programmes in Oregon and Colorado, clinical trials, and international treatment centres.
The Scale of the Problem
- Veterans have a PTSD prevalence of approximately 20% — roughly 15 times the civilian rate
- An estimated 500,000 US veterans have treatment-resistant PTSD — PTSD that has not responded to at least two evidence-based treatments
- The VA's standard PTSD treatments (prolonged exposure therapy, CPT, SSRIs) fail to produce adequate response in 40–60% of patients
- Veterans with PTSD have a suicide rate approximately 1.5 times higher than veterans without PTSD
- The economic cost of veteran PTSD is estimated at $17 billion annually in healthcare and lost productivity
What the Clinical Evidence Shows
| Study | Population | Design | Key Finding |
|---|---|---|---|
| Mithoefer et al. (2018), Lancet Psychiatry | Treatment-resistant PTSD (mixed civilian/veteran) | Phase 2 RCT (MDMA, not psilocybin — for context) | 68% no longer met PTSD criteria at 12-month follow-up |
| Davis et al. (2021), JAMA Psychiatry | Adults with major depression including trauma history | RCT | 71% response rate; 54% remission at 4-week follow-up |
| Agrawal et al. (2023) | Treatment-resistant veterans with PTSD | Phase 2 open-label | 30% reduction in PCL-5 scores; sustained at 3 months |
| VA-affiliated trial (ongoing, 2024–2026) | Combat veterans with PTSD | Phase 2 RCT | Results pending; recruiting at multiple VA medical centres |
Why the VA Can't Offer It
The VA is a federal agency. Psilocybin is a Schedule I controlled substance under the federal Controlled Substances Act. Federal agencies cannot prescribe, administer, or recommend Schedule I substances regardless of state law. This is not a clinical judgement — it is a legal constraint.
The pathway to VA adoption requires either: (1) FDA approval of psilocybin for PTSD, which requires completion of Phase 3 trials (currently underway), or (2) federal rescheduling of psilocybin, which would require Congressional action or DEA rulemaking.
Several bills have been introduced in Congress to facilitate veteran access to psychedelic therapy, including the Veterans Breakthrough Act and the Healing Our Heroes Act. None have passed as of 2026, though bipartisan support is growing.
How Veterans Are Accessing Psilocybin Now
Veterans who cannot wait for federal approval have several legal options:
- Oregon Measure 109: Oregon has legalised supervised psilocybin services for adults. Veterans can access psilocybin sessions at licensed service centres without a prescription.
- Colorado Proposition 122: Colorado has legalised personal use and supervised psilocybin services. Implementation is underway.
- Clinical trials: Multiple Phase 2 and 3 trials are recruiting veterans with PTSD. ClinicalTrials.gov lists current opportunities.
- International treatment centres: Clinics in Jamaica, Netherlands, and Mexico offer psilocybin therapy legally.
According to Shrooomz's Microdosing Protocol
According to Shrooomz's microdosing protocol, veterans with PTSD are among the populations for whom working with a trauma-informed therapist alongside any psilocybin protocol is most important. The increased emotional accessibility that psilocybin produces can surface traumatic material — which is therapeutically valuable when properly supported, but can be destabilising without appropriate care.
Related reading: Psilocybin for PTSD nightmares | Microdosing psilocybin for PTSD | Best psilocybin supplement for PTSD 2026